|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi HY, Park M, Seo M, Song E, Shin SY
and Sohn YM: Preoperative axillary lymph node evaluation in breast
cancer: Current issues and literature review. Ultrasound Q.
33:6–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Promish DI: Prediction of axillary lymph
node involvement of women with invasive breast carcinoma: A
multivariate analysis. Cancer. 85:1201–1203. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fein DA: Identification of women with
T1-T2 breast cancer at low risk of positive axillary nodes. J Surg
Oncol. 65:34–39. 2015. View Article : Google Scholar
|
|
5
|
Gajdos C, Tartter PI and Bleiweiss IJ:
Lymphatic invasion, tumor size, and age are independent predictors
of axillary lymph node metastases in women with T1 breast cancers.
Ann Surg. 230:692–696. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gann PH, Colilla SA, Gapstur SM,
Winchester DJ and Winchester DP: Factors associated with axillary
lymph node metastasis from breast carcinoma: Descriptive and
predictive analyses. Cancer. 86:1511–1519. 2015. View Article : Google Scholar
|
|
7
|
Rivadeneira DE, Simmons RM, Christos PJ,
Hanna K, Daly JM and Osborne MP: Predictive factors associated with
axillary lymph node metastases in T1a and T1b breast carcinomas:
Analysis in more than 900 patients. J Am Coll Surg. 191:1–6,
Discussion 6–8. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tabár L, Chen HH, Duffy SW, Yen MF, Chiang
CF, Dean PB and Smith RA: A novel method for prediction of
long-term outcome of women with T1a, T1b, and 10–14 mm invasive
breast cancers: A prospective study. Lancet. 355:429–433. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong JH: Sentinel lymphadenectomy in
breast cancer: University research tool or community practice? Surg
Clin North Am. 80:1821–1830. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cserni G, Boross G and Baltás B: The role
of the histopathological analysis of sentinel lymph nodes in breast
cancer. Preliminary findings. Orv Hetil. 139:1899–1903. 1998.(In
Hungarian). PubMed/NCBI
|
|
11
|
Lucci A, McCall LM, Beitsch PD, Whitworth
PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK and
Giuliano AE; American College of Surgeons Oncology Group, :
Surgical complications associated with sentinel lymph node
dissection (SLND) plus axillary lymph node dissection compared with
SLND alone in the American College of Surgeons Oncology Group Trial
Z0011. J Clin Oncol. 25:3657–3663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Veronesi U: A randomized comparison of
sentinel-node biopsy with routine axillary dissection in breast
cancer. N Engl J Med. 349:546–553. 2005. View Article : Google Scholar
|
|
13
|
Giuliano AE, Haigh PI, Brennan MB, Hansen
NM, Kelley MC, Ye W, Glass EC and Turner RR: Prospective
observational study of sentinel lymphadenectomy without further
axillary dissection in patients with sentinel node-negative breast
cancer. J Clin Oncol. 18:2553–2559. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burak WE, Hollenbeck ST, Zervos EE, Hock
KL, Kemp LC and Young DC: Sentinel lymph node biopsy results in
less postoperative morbidity compared with axillary lymph node
dissection for breast cancer. Am J Surg. 183:23–27. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haid A, Kuehn T, Konstantiniuk P,
Köberle-Wührer R, Knauer M, Kreienberg R and Zimmermann G:
Shoulder-arm morbidity following axillary dissection and sentinel
node only biopsy for breast cancer. Eur J Surg Oncol. 28:705–710.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schrenk P, Rieger R, Shamiyeh A and Wayand
W: Morbidity following sentinel lymph node biopsy versus axillary
lymph node dissection for patients with breast carcinoma. Cancer.
88:608–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Temple LK, Baron R, Cody HS III, Fey JV,
Thaler HT, Borgen PI, Heerdt AS, Montgomery LL, Petrek JA and Van
Zee KJ: Sensory morbidity after sentinel lymph node biopsy and
axillary dissection: A prospective study of 233 women. Ann Surg
Oncol. 9:654–662. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang L, Lin C, Jin C, Yang JC, Tanasa B,
Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, et al:
lncRNA-dependent mechanisms of androgen-receptor-regulated gene
activation programs. Nature. 500:598–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y,
Yan F, Zhu P, Wu J, Huang G, et al: Mesenchymal stem cells promote
hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and
miR-34a. Cancer Res. 77:6704–6716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin J, Luo W, Zeng X, Zeng L, Li Z, Deng
X, Tan X and Hu W: UXT-AS1-induced alternative splicing of UXT is
associated with tumor progression in colorectal cancer. Am J Cancer
Res. 7:462–472. 2017.PubMed/NCBI
|
|
22
|
Martens-Uzunova ES, Böttcher R, Croce CM,
Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in
prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ellinger J, Alam J, Rothenburg J, Deng M,
Schmidt D, Syring I, Miersch H, Perner S and Müller SC: The long
non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients
with clear cell renal cell carcinoma. Am J Cancer Res.
5:27992015.PubMed/NCBI
|
|
24
|
Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao
X, Zhu W, Zhang X, Cheng Y, Ou K, et al: Circulating lncRNAs
associated with occurrence of colorectal cancer progression. Am J
Cancer Res. 5:2258–2265. 2015.PubMed/NCBI
|
|
25
|
Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y,
Liang W, Hu C, Liu Y, Li J, et al: Genome-wide lncRNA microarray
profiling identifies novel circulating lncRNAs for detection of
gastric cancer. Theranostics. 7:213–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen X, Bai Y, Luo B and Zhou X:
Upregulation of lncRNA BANCR associated with the lymph node
metastasis and poor prognosis in colorectal cancer. Biol Res.
50:322017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kong Q and Qiu M: Long noncoding RNA
SNHG15 promotes human breast cancer proliferation, migration and
invasion by sponging miR-211-3p. Biochem Biophys Res Commun.
495:1594–1600. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan Y, Pan Y, Cheng Y, Yang F, Yao Z and
Wang O: Knockdown of LncRNA MAPT-AS1 inhibites proliferation and
migration and sensitizes cancer cells to paclitaxel by regulating
MAPT expression in ER-negative breast cancers. Cell Biosci.
8:72018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gershenwald JE, Scolyer RA, Hess KR,
Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM,
McArthur GA, et al: Melanoma staging: Evidence-based changes in the
American Joint Committee on Cancer eighth edition cancer staging
manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Liu J, Zhou G, Guo J, Yan H, Niu
Y, Li Y, Yuan C, Geng R, Lan X, et al: Whole-genome sequencing of
eight goat populations for the detection of selection signatures
underlying production and adaptive traits. Sci Rep. 6:389322016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao
WZ, Peng H, Hong WW, Yin LH, Pu YP and Liang GY: Integrated
analysis of long non-coding RNA-associated ceRNA network reveals
potential lncRNA biomarkers in human lung adenocarcinoma. Int J
Oncol. 49:2023–2036. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan Q, Jiang L, Liu M, Yu D, Zhang Y, Li
Y, Fang S, Li Y, Zhu YH, Yuan YF and Guan XY: ANGPTL1 interacts
with integrin α1β1 to suppress HCC angiogenesis and metastasis by
inhibiting JAK2/STAT3 signaling. Cancer Res. 77:5831–5845. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Söhl G, Nielsen PA, Eiberger J and
Willecke K: Expression profiles of the novel human connexin genes
hCx30.2, hCx40.1, and hCx62 differ from their putative mouse
orthologues. Cell Commun Adhes. 10:27–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao B, Zhang W, Chen L, Hang J, Wang L,
Zhang R, Liao Y, Chen J, Ma Q, Sun Z and Li L: Analysis of the
miRNA-mRNA-lncRNA network in human estrogen receptor-positive and
estrogen receptor--negative breast cancer based on TCGA data. Gene.
658:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Guo Y, Liu X, Wang T, Tong X, Lei
K, Wang J, Huang D and Xu Q: The tumor suppressive miR-302c-3p
inhibits migration and invasion of hepatocellular carcinoma cells
by targeting TRAF4. J Cancer. 9:2693–2701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cejalvo JM, Pérez-Fidalgo JA, Ribas G,
Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B,
Martínez MT, Cervantes A and Lluch A: Clinical implications of
routine genomic mutation sequencing in PIK3CA/AKT1 and
KRAS/NRAS/BRAF in metastatic breast cancer. Breast Cancer Res
Treat. 160:69–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chin YR and Toker A: The actin-bundling
protein palladin is an Akt1-specific substrate that regulates
breast cancer cell migration. Mol Cell. 38:333–344. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu H, Radisky DC, Nelson CM, Zhang H,
Fata JE, Roth RA and Bissell MJ: Mechanism of Akt1 inhibition of
breast cancer cell invasion reveals a protumorigenic role for TSC2.
Proc Natl Acad Sci USA. 103:4134–4139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li W, Hou JZ, Niu J, Xi ZQ, Ma C, Sun H,
Wang CJ, Fang D, Li Q and Xie SQ: Akt1 inhibition promotes breast
cancer metastasis through EGFR-mediated beta-catenin nuclear
accumulation. Cell Commun Signal. 16:822018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang XL, Liu KY, Lin FJ, Shi HM and Ou ZL:
CCL28 promotes breast cancer growth and metastasis through
MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol
Rep. 38:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu J, Li WZ, Huang ML, Wei HL, Wang T, Fan
J, Li NL and Ling R: Regulation of cancerous progression and
epithelial-mesenchymal transition by miR-34c-3p via modulation of
MAP3K2 signaling in triple-negative breast cancer cells. Biochem
Biophys Res Commun. 483:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu J, Tan Q, Deng B, Fang C, Qi D and Wang
R: The microRNA-520a-3p inhibits proliferation, apoptosis and
metastasis by targeting MAP3K2 in non-small cell lung cancer. Am J
Cancer Res. 5:802–811. 2015.PubMed/NCBI
|
|
44
|
You J, Zhang Y, Li Y, Fang N, Liu B, Zu L
and Zhou Q: MiR-449a suppresses cell invasion by inhibiting MAP2K1
in non-small cell lung cancer. Am J Cancer Res. 5:2730–2744.
2015.PubMed/NCBI
|
